Pronk L C, Stoter G, Verweij J
Department of Medical Oncology, Rotterdam Cancer Institute/Dr Daniel den Hoed Kliniek, The Netherlands.
Cancer Treat Rev. 1995 Sep;21(5):463-78. doi: 10.1016/0305-7372(95)90030-6.
Docetaxel is a new semi-synthetic taxoid, which acts as an antimicrotubule agent and is now clinically available. Clinical studies of docetaxel as a single agent and in combination with other cytotoxic drugs reveals favourable response rates in a number of solid tumor types. Docetaxel appears to have great potential in advanced breast cancer as first or secondline chemotherapy. The dose-limiting toxicity is an early and short-lasting neutropenia. Fluid retention is a cumbersome, sometimes disabling, side-effect. Other side-effects are usually mild and include alopecia, myalgia, mucostitis, neuropathy, hypersensitivity reaction, nail changes and cutaneous reactions.
多西他赛是一种新型半合成紫杉烷类药物，作为一种抗微管药物，目前已应用于临床。多西他赛单药及与其他细胞毒性药物联合应用的临床研究表明，其在多种实体瘤类型中具有良好的缓解率。多西他赛作为一线或二线化疗药物，在晚期乳腺癌治疗中似乎具有巨大潜力。剂量限制性毒性是早期且短暂的中性粒细胞减少。液体潴留是一种麻烦的、有时甚至会导致功能障碍的副作用。其他副作用通常较轻，包括脱发、肌痛、粘膜炎、神经病变、过敏反应、指甲改变和皮肤反应。
